department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Prednisone · pharmadog

pharmadog
drugs
Prednisone

drug

patient view →

prednisone

Marketedupdated 2mo ago

by Vintage Pharmaceuticals Inc (Inactive)

Approved

community read0 votes

indications

investigational

Multiple SclerosisIBD (Crohn's + UC)Rheumatoid ArthritisPsoriasisLupusAsthma

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Prednisone

generic

prednisone [INN]

indication

Aspiration Pneumonitis

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 13m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 3, 2027

~1.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

Jan 7, 2028formulationUS 81682181.5y
Aug 3, 2027method-of-use (U-1362)US 95046991.1y
Aug 3, 2027method-of-use (U-1362)US 95046991.1y
Aug 3, 2027method-of-use (U-1362)US 95046991.1y

🐶 often sniffed alongside

top 4

tagApproval2 co-mentions · 1 sources
drugprednisone DR1 co-mentions · 1 sources
drugPrednisone Hikma1 co-mentions · 1 sources
tagSmall Molecule1 co-mentions · 1 sources

Trials studying prednisone

phase1A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Canceractive not recruitingn=136
phase1A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Canceractive not recruitingn=57
phase3A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)recruitingn=960
phase2A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participantsrecruitingn=40
phase2Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemiarecruitingn=30
phase3A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)active not recruitingn=925
phase1M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)active not recruitingn=60
phase2A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studiesrecruitingn=60

more trials →